1155846-90-4

Upstream product

• 174180-76-8 3-bromomethylpyrazolo[3,4-b]pyridine-1-carboxylic acid tert-butyl ester 
• 174180-77-9 tert-butyl 3-methyl-1H-pyrazolo[3,4-b]pyridine-1-carboxylate 
• 116834-96-9 3-methyl-1H-pyrazolo[3,4b]pyridine 
• 55676-21-6 3-acetyl-2-chloropyridine 
• 2942-59-8 2-chloronicotinic acid 
• 1155846-89-1 3-(azidomethyl)-1H-pyrazolo[3,4-b]pyridine 

Downstream Products

• 1155846-50-6 3-chloro-5-({5-chloro-3-fluoro-6-[(1H-pyrazolo[3,4-b]pyridin-3-ylmethyl)amino]pyridin-2-yl}oxy)benzonitrile 
• 1155847-18-9 3-({2-(benzyloxy)-3-chloro-6-[(1H-pyrazolo[3,4-b]pyridin-3-ylmethyl)amino]pyridin-4-yl}oxy)-5-chlorobenzonitrile 
• 1155846-64-2 3-chloro-5-({3-chloro-2,5-difluoro-6-[(1H-pyrazolo[3,4-b]pyridin-3-ylmethyl)amino]pyridin-4-yl}oxy)benzonitrile 

Relevant academic research and scientific papers

Discovery of (S)-1-(1-(Imidazo[1,2- a ]pyridin-6-yl)ethyl)-6-(1-methyl-1 H -pyrazol-4-yl)-1 H -[1,2,3]triazolo[4,5- b ]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal-Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

HGF/c-Met signaling has been implicated in human cancers. Herein we describe the invention of a series of novel triazolopyrazine c-Met inhibitors. The structure-activity relationship of these compounds was investigated, leading to the identification of compound 28, which demonstrated favorable pharmacokinetic properties in mice and good antitumor activities in the human glioma xenograft model in athymic nude mice.

NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

Heteroaromatic compounds of Formula (I), are HIV reverse transcriptase inhibitors, wherein ring A is: (ii-a), (ii-b), (ii-c), (ii-d), or (ii-e); and wherein n, L, M, U, X, Y, Z, RE, RF, R1, R2A, R2B,